A real world, observational, cohort, global study analysing first line Osimertinib in EGFRm NSCLC
Latest Information Update: 08 Mar 2021
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Mar 2021 New trial record
- 31 Jan 2021 Trial design, presented at the 2020 World Conference on Lung Cancer